Increased SARS-CoV-2-related hospitalization and mortality in rheumatoid arthritis patients receiving rituximab therapy-a monocentric retrospective study.

作者信息

Wang Chrong-Reen, Hsu Chih-Hui, Lin Wei-Chieh

机构信息

Division of Rheumatology and Immunology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.

Biostatistics Consulting Center, Clinical Medicine Research Center, National Cheng Kung University Hospital, Tainan, Taiwan.

出版信息

J Microbiol Immunol Infect. 2025 Apr;58(2):272-275. doi: 10.1016/j.jmii.2025.01.004. Epub 2025 Jan 28.

From 2022 April to 2024 August, retrospective analyses by multivariable logistic regression were conducted in 341 rheumatoid arthritis patients receiving rituximab (RTX), tofacitinib (TOF) or disease-modifying-anti-rheumatic drug (DMARD) alone therapy. Compared to DMARD alone or TOF treatment, RTX therapy had increased adjusted odds ratios of SARS-CoV-2-related hospitalization, pneumonia and mortality.